CENTRAL COMPOSITE FACE-CENTERED DESIGN-BASED OPTIMISATION, DEVELOPMENT AND CHARACTERISATION OF FAVIPIRAVIR-LOADED PLGA NANOPARTICLES

Objective: The objective of this study is to fabricate favipiravir-loaded PLGA nanoparticulate systems that can increase the solubility along with sustained release favipiravir. Methods: Poly (D, L-lactic-co-glycolide) (PLGA) were prepared by nanoprecipitation method. A 3-factor, 2-level central composite face-centered design was employed effect formulation variables having a concentration PLGA, polyvinyl alcohol (PVA) and stirring rate as critical attributes particle size, drug entrapment efficiency, percentage cumulative quality on favipiravir nanoparticles. Drug interaction studies performed FTIR DSC. Surface morphology analysed scanning electron microscopy (FEI Quanta 250 FEG, USA). Particle zeta potential, polydispersity index nanoparticle analyser SZ-100 (HORIBA Scientific nanopartica, Japan). In vitro using UV-Visible spectrophotometer at λmax 234 nm. data obtained fitted into various mathematical kinetic models. Results: numerical optimization process predicted level 69.96 mg, PVA 4.99%, 799 rpm for optimised formulation. low relative error confirms validation model. had 77.65% efficiency size 109.7 nm percent showed 86.46% over 720 min. found follow first-order kinetics anomalous non-Fickian diffusion kinetics. Conclusion: Hence, such an attempt fabrication may be useful